Table 1.
Reports about intracranial response to EGFR-TKIs without WBRT in lung cancer patients (adenocarcinoma)
| Author | Pt | TKI agent used | WBRT | Intracranial response rate, % | CNS failure interval, ms | EGFR mutation |
|---|---|---|---|---|---|---|
| Kim et al. (2009) [2] | 23 | gefitinib 250 mg (n = 16) or erlotinib 150 mg (n = 7) | ND | 73.9 | 19.3 | confirmed (Y) |
| Park et al. (2012) [4] | 28 | gefitinib 250 mg (n = 22) or erlotinib 150 mg (n = 6) | ND | 83 | 12.6 | confirmed (Y) |
| Iuchi et al. (2013) [7] | 41 | gefitinib 250 mg | ND | 87.8 | 14.5 | confirmed (Y) |
| Zeng et al. (2012) [6] | 90 | gefitinib 250 mg | done (n = 45)(40 Gy) ND (n = 45) | done: 64.4 ND: 26.7 | done: 10.6 ND: 6.57 | unconfirmed |
| Welsh et al. (2013) [8] | 40 | erlotinib 150 mg | done (35 Gy) | 86 | 8.0 | Y (n = 8) N (n = 9) unconfirmed (n =23) |
| Zhuang et al. (2013) [16] | 23 | erlotinib 150 mg | done (30 Gy) | 95.65 | Y: 11.2 N: 9.6 | Y (n = 11) N (n = 12) |
Pt = Number of patients; Y = yes; N= no; ND = not done.